TransCode Therapeutics ( ($RNAZ) ) just unveiled an update. On January 6, 2026, TransCode Therapeutics announced the publication in the Journal of ...
Publishes Preclinical Data Supporting TTX-MC138 For Glioblastoma. TransCode Therapeutics (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead ...
Sabrina Lewandowski woke up one morning 23 years ago with a headache that should have killed her. The cause was a stage four glioblastoma multiforme – a particularly insidious brain tumor that most ...
Glioblastoma multiforme (GBM) is a highly aggressive and malignant brain tumor that is resistant to many treatments. Unfortunately, the median survival time after diagnosis is 15 months. GBM arises ...
BRISBANE, Australia, Oct. 7, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully ...
Exousia Pro's exome-based treatment for GBM has received FDA orphan drug designation, offering incentives like tax benefits and market exclusivity. The company's exosomal technology delivers genetic ...
Mia Love, wife, mother, mayor and the first Black Republican woman in the U.S. House of Representatives, died at home of glioblastoma multiforme brain cancer on March 23, 2025, surrounded by her ...
Glioblastoma multiforme is an aggressive brain tumor that mainly affects adults. Approximately 30,000 people in the U.S. are diagnosed with GBM every year and patients have a 5-year survival rate of 7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback